Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

Podcasts
Case Managers, Telepsychiatry Offer Consistency in Schizophrenia Treatment
08/24/2022
Amber Hoberg, NP, discusses meeting her patients with schizophrenia "where they are" to provide treatment.
Amber Hoberg, NP, discusses meeting her patients with schizophrenia "where they are" to provide treatment.
Amber Hoberg, NP, discusses...
08/24/2022
Psych Congress Network

Advertisement

News
Study Supports Oral Ketamine Formulation as Potential Treatment for Acute Pain
08/23/2022
Specialty pharmaceutical company Vitalis Analgesics has published a randomized, controlled trial demonstrating the effectiveness of its proprietary VTS aspirin/ketamine formulation, known as VTS-85, as a potential oral treatment for acute...
Specialty pharmaceutical company Vitalis Analgesics has published a randomized, controlled trial demonstrating the effectiveness of its proprietary VTS aspirin/ketamine formulation, known as VTS-85, as a potential oral treatment for acute...
Specialty pharmaceutical company...
08/23/2022
Psych Congress Network
News
Past Psychomotor Symptoms Predict Abnormal Reward-Based Reinforcement Learning in Remitted MDD
08/22/2022
A history of psychomotor retardation predicts altered reward-based reinforcement learning in people with remitted major depressive disorder (MDD), according to a study published in the Journal of Psychiatric Research.
A history of psychomotor retardation predicts altered reward-based reinforcement learning in people with remitted major depressive disorder (MDD), according to a study published in the Journal of Psychiatric Research.
A history of psychomotor...
08/22/2022
Psych Congress Network
News
Extended Release Amphetamine Now Available for Children and Adults With ADHD
08/22/2022
After receiving US Food and Drug Administration approval last fall, Dyanavel XR (amphetamine) extended-release tablets are now available in pharmacies for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients 6 years...
After receiving US Food and Drug Administration approval last fall, Dyanavel XR (amphetamine) extended-release tablets are now available in pharmacies for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients 6 years...
After receiving US Food and Drug...
08/22/2022
Psych Congress Network

Advertisement

News
Antipsychotics During Pregnancy Do Not Hinder Children’s Test Performance
08/22/2022
Antipsychotic prescriptions during pregnancy did not appear to be associated with standardized test scores in offspring.
Antipsychotic prescriptions during pregnancy did not appear to be associated with standardized test scores in offspring.
Antipsychotic prescriptions...
08/22/2022
Psych Congress Network
News
AUD Increases Mortality Risk for Cannabis Use Disorder Patients
08/18/2022
Alcohol use disorder (AUD) has been shown to increase mortality risk among individuals with cannabis use disorder, according to a new study published online ahead of print by the journal Psychiatry Research.
Alcohol use disorder (AUD) has been shown to increase mortality risk among individuals with cannabis use disorder, according to a new study published online ahead of print by the journal Psychiatry Research.
Alcohol use disorder (AUD) has...
08/18/2022
Psych Congress Network
News
Midlife Depression More Common in People With Genetic Predisposition to Alzheimer Disease
08/16/2022
A greater genetic burden for Alzheimer disease is associated with a higher likelihood of midlife depression in people with unimpaired cognition.
A greater genetic burden for Alzheimer disease is associated with a higher likelihood of midlife depression in people with unimpaired cognition.
A greater genetic burden for...
08/16/2022
Psych Congress Network

Advertisement

News
Senescence Markers Linked with Worse Treatment Outcomes in Late-Life Depression
08/15/2022
Higher scores on the SASP index significantly linked to worse treatment outcomes in older adults with major depressive episode.
Higher scores on the SASP index significantly linked to worse treatment outcomes in older adults with major depressive episode.
Higher scores on the SASP index...
08/15/2022
Psych Congress Network
News
Phase 3 Trial Shows Efficacy of Extended-Release Amphetamine Tablets in Adult ADHD
08/15/2022
Adults with ADHD who took amphetamine extended-release tablets had statistically significant improvement in symptoms.
Adults with ADHD who took amphetamine extended-release tablets had statistically significant improvement in symptoms.
Adults with ADHD who took...
08/15/2022
Psych Congress Network
News
Leisure Activities Associated With Reduced Dementia Risk
08/12/2022
Leisure activities may help lower the risk of dementia.
Leisure activities may help lower the risk of dementia.
Leisure activities may help...
08/12/2022
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use